Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Qiagen NV    QGEN   NL0000240000


News SummaryMost relevantAll newsSector newsTweets 

QIAGEN NV : Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Second Quarter 2010 Financial Results Call Set for August 10

share with twitter share with LinkedIn share with facebook
share via e-mail
08/03/2010 | 02:05pm CET

VENLO, The Netherlands, Aug. 3 /PRNewswire-FirstCall/ -- QIAGEN N.V. (Nasdaq: QGEN) today announced the Webcast of its second quarter 2010 financial results call. The Webcast will take place at 9:30 a.m. EDT on Tuesday, August 10, and will include remarks by Peer M. Schatz, President and Chief Executive Officer, and Roland Sackers, Chief Financial Officer.

                    Webcast of QIAGEN's second quarter 2010 financial
    What:            results call

    When:           9:30 a.m. EDT on August 10

                    The Webcast is accessible at www.qiagen.com/goto/
    Where:           ConferenceCall

    How:            Log on to the Web at the address above

                    The corresponding presentation slides will be
                    available for download in the investor relations
                    section of QIAGEN's Web site at www.qiagen.com/

                    Andreas Marathovouniotis, Russo Partners, (212)
    Contact:        845-4235

QIAGEN N.V., a Netherlands holding company, is the leading provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 consumable products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include what is considered to be the broadest panel of molecular diagnostic tests available worldwide. This panel includes the only FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer.

QIAGEN employs more than 3,500 people in over 30 locations worldwide. Further information about QIAGEN can be found at www.qiagen.com.

(Minimum Requirements to listen to broadcast: The RealPlayer software, downloadable free from http://www.real.com/products/player/index.html, or The Windows Media Player, downloadable free from www.microsoft.com and at least a 14.4Kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to prnwebcast@multivu.com.)


share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on QIAGEN NV
01/18 QIAGEN : Announces Details for Completion of Approximately $250 Million Syntheti..
01/18 QIAGEN N.V. : to Report Fourth Quarter and Full Year of 2016 Results
01/10 QIAGEN : Singulex Enters into Collaboration with QIAGEN to Develop Companion Dia..
01/09 QIAGEN : Enhances Bioinformatics Portfolio with Acquisition of OmicSoft
01/09 QIAGEN : Announces Comprehensive Range of Enhancements for GeneReader NGS System
01/09 QIAGEN : enhances bioinformatics portfolio with acquisition of OmicSoft
01/09 QIAGEN : announces comprehensive range of enhancements for GeneReader NGS System
01/09 QIAGEN : Submits QuantiFERON®-TB Gold Plus for U.S. Regulatory Approval
2016 QIAGEN : welcomes new evidence-based tuberculosis testing guidelines from U.S. p..
2016 QIAGEN : GeneReader NGS System Streamlines Data Management for Labs
More news
Sector news : Biotechnology & Medical Research - NEC
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
01/17 Even A $100M Series A Can't Save The Medtech Venture Climate
01/17 Qiagen (QGEN) Presents At German Corporate Conference 2017
01/11 Qiagen NV (QGEN) presents at 35th Annual J.P. Morgan Healthcare Conference
2016 Qiagen N.V. 2016 Q3 - Results - Earnings Call Slides